ADJACENT DOMAIN — ROADMAP
A parallel domain engine for antibacterial, antiviral, antifungal, and antiparasitic pharmacology. Same cascade architecture as the human Flux Pharmacology engine; pathogen-specific content at every step. This page is a roadmap document — nothing here is shipping today.
Status: mixed-tier roadmap view. The binding-affinity layer reaches most pathogen targets today via the same target-engagement engine that scored CASF-2016 (r = 0.772) on diverse target classes — so most Phase 3 (Target engagement) chips below are in pilot. Pathogen-specific infrastructure (envelope crossing, efflux modeling, MIC determination, biofilm / persister states, lifecycle-stage selectivity) is on the roadmap.
Full domain delivery is gated on the human-pharmacology cascade reaching primary-endpoint validation across its full scope. Microbial pharmacology is treated as a parallel domain engine that inherits the cascade architecture and the target-engagement engine but has its own envelopes, resistance enzymes, mechanism outputs (MIC, MBC, time-kill kinetics), and validation datasets (CLSI / EUCAST MIC databases, ChEMBL antimicrobial subsets, CO-ADD, Stanford HIVdb, MARS, MMV, NCATS).
How to read these tiers. Validated items have published benchmark numbers — use as primary screening criterion. Pilot items run the same physics that validated other targets in the same family — usable as primary screening criterion with the per-endpoint validation caveat. In-development items are operational prototypes with newer or scope-capped physics — treat output as directional input and cross-check experimentally. Future items aren't available today.
Each tab shows the planned cascade content for that domain. The cascade structure (envelope crossing → accumulation → target engagement → mechanism → selectivity) is shared across domains; the specific modules differ at every step.
Microbial pharmacology shares the canonical cascade architecture (entry → accumulation → target engagement → mechanism → decision) but has its own targets, envelopes, resistance enzymes, and validation datasets. Host-vs-pathogen selectivity is composed at the result-assembly layer by running the human cascade in parallel against host homologs. Planned phasing: bacterial flagship → antiviral flagship → antifungal + antiparasitic → resistance + combinations → productization.
If your program would benefit from microbial pharmacology capabilities — antimicrobial discovery, resistance liability, host-vs-pathogen selectivity — we'd like to hear about the use case as we plan execution sequencing.
Our human-pharmacology cascade is validated and shipping — 5 of 8 ADMET endpoints at public-benchmark SOTA, all 8 modes of binding physics operational.
View Life Sciences →Tell us about your antimicrobial discovery program so we can prioritise the first wave correctly.
Discuss this roadmap →